Drug Profile
Granulocyte colony stimulating factor long-acting - Genexine
Alternative Names: G-CSF-hyFc; GCSF-hFc; GX-G03; GX-G3; HyGrastimLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Genexine
- Developer Boryung Pharmaceutical; Genexine; Ilkogen
- Class Adjuvants; Glycoproteins; Granulocyte colony-stimulating factors; Granulocyte-macrophage colony-stimulating factors; Recombinant fusion proteins
- Mechanism of Action Haematopoietic cell growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Neutropenia
Most Recent Events
- 28 Sep 2021 Phase II development is still ongoing for Neutropenia in Bulgaria (Genexine pipeline, September 2021)
- 28 Sep 2021 Genexine plans a phase III trial in Neutropenia (Genexine pipeline, September 2021)
- 01 Jun 2019 Safety and pharmacokinetics data from a phase II trial in Non-Hodgkin’s lymphoma presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)